Proceedings of the International scientific and practical conference ―Science at the Frontier of Progress‖ (June 8-10, 2026) / Publisher website: www.naukainfo.com. – Paris, France, 2026. - 178 p.

25 cytokine-induced STAT3 phosphorylation in whole blood from healthy individuals and patients with PMF and IP [14]. In general, the understanding of the pathogenesis, diagnosis, and treatment of CMPN has been repeatedly revised over the long history of its study. In recent years, significant progress has been made in establishing the role of the JAK/STAT signaling pathway in Ph-negative CMPN. This has led to the identification of molecular targets for directed pathogenetic therapy with targeted drugs capable of modifying the course of these diseases and significantly increasing the duration and quality of life of patients, and has also allowed the creation of an international unified system of criteria for diagnosis, monitoring and assessment of response to treatment. The continuous integration of molecular diagnostics, new drugs targeting STATs, and combination therapies is necessary to improve therapeutic accuracy and clinical outcomes. Future studies should offer a deeper understanding of the influence of the basic mechanisms of the JAK/STAT signaling pathway on the development of the disease, which should maximize the effectiveness of the use of Janus kinase inhibitor drugs and minimize side effects in patients at different stages of these diseases. REFERENCES: 1. Liang D. JAK/STAT in leukemia: a clinical update./ Liang D., Wang Q., Zhang W.et al. //Liang et al. Molecular Cancer (2024) 23:25. P 1-12. https://doi.org/10.1186/s12943-023-01929-1 2. Bousoik E. Do We Know Jack About JAK? A Closer Look at JAK/STAT Signaling Pathway Front/ Bousoik E, Montazeri Aliabadi H.//Oncol. 2018;8:287. doi:10.3389/fonc.2018.00287 3. Xin P. The role of JAK/STAT signaling pathway and its inhibitors in diseases./ Xin P, Xu X, Deng C, et al // IntImmunopharmacol. 2020;80:106210. doi:10.1016/j.intimp.2020.106210 4. Mohamed J. The JAK/STAT pathway: key mechanism in gene activation, disease regulation, and emerging therapeutic targets /Mohamed J., Ezat H,, Abdelrahman R. et al. Mol Biol Rep. 2026 May 9;53(1):732. doi: 10.1007/s11033-026-11847-2. 5. Xue C. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer./ Chen Xue C., Yao Q., Gu1 X, // Signal Transduction and Targeted Therapy (2023) May 19;8(1):204 doi: 10.1038/s41392-023-01468-7. 6. Djidjik R. JAK/STAT in human diseases: a common axis in immunodeficiencies and hematological disorders. Review./ Djidjik R., Mahammed L.L., Berkani L.M. et al.// Frontiers in Immunology. 16:1669688. P 1-30. doi: 10.3389/fimmu. 2025.1669688 7. Helbig G. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors./ Med Oncol. 2018;35(9):119. Published 2018 Aug 3. doi:10.1007/s12032-018-1187- 3 8. Khoury J.D, Solary E., Abla O., Akkari Y., Alaggio R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/ Dendritic Neoplasms. Leukemia (2022) 36:1703–1719; https://doi.org/10.1038/s41375-022-01613-1 9. Xiaoyi Hu. The JAK/STAT signaling pathway: from bench to clinic Signal Transduction and Targeted Therapy/ Xiaoyi Hu, Jing li, Maorong Fu et all.// ( 2021) 6:402 https://doi.org/10.1038/s41392-021- 00791-1 10. Hubbard SR. Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase. Front Endocrinol (Lausanne). 2018;8:361. doi: 10.3389/fendo.2017.00361 11. Mead AJ. Myeloproliferative neoplasm stem cells./ Mead AJ, Mullally A.//Blood. 2017;129(12):1607- 16. 12. McPherson S. Epigenetics in Myeloproliferative Neoplasms. / McPherson S, McMullin MF, Mills K. J Cell Mol Med. 2017;21(9):1660–1667. doi:10.1111/jcmm.13095 13. Musumeci F. An Update on JAK Inhibitors./ Musumeci F, Greco C, Giacchello I, et al. // Curr Med Chem. 2019;26(10):1806–1832. doi: 10.2174/0929867325666180327093502 14. Greenfield G. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms./ Greenfield G, McPherson S, Mills K, et.all// J Transl Med. 2018;16(1):360. doi:10.1186/s12967-018-1729-7